Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes

Aims/hypothesisPreviously, we proposed that data-driven metabolic subtypes predict mortality in type 1 diabetes. Here, we analysed new clinical endpoints and revisited the subtypes after 7 years of additional follow-up.MethodsFinnish individuals with type 1 diabetes (2059 men and 1924 women, insulin treatment before 35 years of age) were recruited by the national multicentre FinnDiane Study Group. The participants were assigned one of six metabolic subtypes according to a previously published self-organising map from 2008. Subtype-specific all-cause and cardiovascular mortality rates in the FinnDiane cohort were compared with registry data from the entire Finnish population. The rates of incident diabetic kidney disease and cardiovascular endpoints were estimated based on hospital records.ResultsThe advanced kidney disease subtype was associated with the highest incidence of kidney disease progression (67.5% per decade, p < 0.001), ischaemic heart disease (26.4% per decade, p < 0.001) and all-cause mortality (41.5% per decade, p < 0.001). Across all subtypes, mortality rates were lower in women compared with men, but standardised mortality ratios (SMRs) were higher in women. SMRs were indistinguishable between the original study period (1994–2007) and the new period (2008–2014). The metabolic syndrome subtype predicted cardiovascular deaths (SMR 11.0 for men, SMR 23.4 for women, p < 0.001), and women with the high HDL-cholesterol subtype were also at high cardiovascular risk (SMR 16.3, p < 0.001). Men with the low-cholesterol or good glycaemic control subtype showed no excess mortality.Conclusions/interpretationData-driven multivariable metabolic subtypes predicted the divergence of complication burden across multiple clinical endpoints simultaneously. In particular, men with the metabolic syndrome and women with high HDL-cholesterol should be recognised as important subgroups in interventional studies and public health guidelines on type 1 diabetes.

[1]  C. Forsblom,et al.  Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study , 2011, BMJ : British Medical Journal.

[2]  Morten Wang Fagerland,et al.  All-cause mortality in a nationwide cohort of childhood-onset diabetes in Norway 1973–2013 , 2015, Diabetologia.

[3]  M. Breton,et al.  Fluctuations of Hyperglycemia and Insulin Sensitivity Are Linked to Menstrual Cycle Phases in Women With T1D , 2015, Journal of diabetes science and technology.

[4]  P. Cleary,et al.  The Long-Term Effects of Type 1 Diabetes Treatment andComplications on Health-Related Quality of Life A 23-year follow-up of the Diabetes Control and Complications / Epidemiology of Diabetes Interventions and Complications cohort , 2013 .

[5]  Tore K Kvien,et al.  Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis , 2007, BMC Medical Genetics.

[6]  Tony Badrick,et al.  Higher Dimensions : Machine-Learning and Enhanced Prediction from Routine Clinical Chemistry Data , 2016 .

[7]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[8]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[9]  M. Woodward,et al.  Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. , 2015, The lancet. Diabetes & endocrinology.

[10]  L. Kuller,et al.  Coronary artery disease in IDDM. Gender differences in risk factors but not risk. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Gretchen A. Piatt,et al.  Deficiencies of Cardiovascular Risk Prediction Models for Type 1 Diabetes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[12]  C. Forsblom,et al.  Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients , 2003, Diabetologia.

[13]  Thomas J. Songer,et al.  Improvements in the Life Expectancy of Type 1 Diabetes , 2012, Diabetes.

[14]  R. Karas,et al.  Molecular and Cellular Basis of Cardiovascular Gender Differences , 2005, Science.

[15]  P. Clarke,et al.  Recent trends in life expectancy for people with type 1 diabetes in Sweden , 2016, Diabetologia.

[16]  J. Shaw,et al.  Age-Specific Trends From 2000–2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People , 2016, Diabetes Care.

[17]  C. Forsblom,et al.  Metabolic Syndrome as a Risk Factor for Cardiovascular Disease, Mortality, and Progression of Diabetic Nephropathy in Type 1 Diabetes , 2009, Diabetes Care.

[18]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[19]  T. Orchard,et al.  High-density lipoprotein cholesterol in diabetes: is higher always better? , 2011, Journal of clinical lipidology.

[20]  Merlin C. Thomas,et al.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.

[21]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[22]  K. Kaski,et al.  Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes , 2008, Diabetes.

[23]  M. Taskinen,et al.  Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes , 2009, Diabetologia.

[24]  W. Herman,et al.  A Meta-Analysis of the Relative Risk of Mortality for Type 1 Diabetes Patients Compared to the General Population: Exploring Temporal Changes in Relative Mortality , 2014, PloS one.

[25]  V. Fuster,et al.  Cardiovascular risk factors in patients with chronic kidney disease , 2009, Nature Reviews Cardiology.

[26]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[27]  B. Carstensen,et al.  Time trends in mortality rates in type 1 diabetes from 2002 to 2011 , 2013, Diabetologia.

[28]  K. Kaski,et al.  1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death , 2008, Molecular systems biology.

[29]  A. Rigby,et al.  Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes , 2007, Diabetes Care.

[30]  Alex P. Reiner,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[31]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[32]  David Meyre,et al.  From big data analysis to personalized medicine for all: challenges and opportunities , 2015, BMC Medical Genomics.

[33]  K. Secnik,et al.  Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain , 2005, Current medical research and opinion.

[34]  T. Orchard,et al.  The Prediction of Major Outcomes of Type 1 Diabetes: a 12-Year Prospective Evaluation of Three Separate Definitions of the Metabolic Syndrome and Their Components and Estimated Glucose Disposal Rate , 2007, Diabetes Care.